GSK “Delighted” By India’s Supreme Court Ruling In 10-Year Exclusive Marketing Rights Battle Over Avandia

MUMBAI - The Supreme Court of India has upheld a Calcutta High Court decision to grant exclusive marketing rights to GlaxoSmithKline's anti-diabetes drug Avandia in a landmark judgment that will have wide repercussions on product patent applications by multinational companies in India